ZILA Zila (MM)

Zila, Inc.'s (Nasdaq: ZILA) wholly-owned subsidiary, Zila Nutraceuticals, Inc., maker of Ester-C(R) and Ester-E(R), has appointed industry veteran Bernie Landes as its Vice President and General Manager. "Bernie's unique background and experience in the nutraceutical market is ideal for leading the continued growth and evolution of our Ester(TM) branded products as we position the business to quickly achieve our larger strategic objectives for the Company," said Douglas Burkett, Ph.D., Chairman, Chief Executive Officer and President of Zila, Inc. "As we diversify and grow our customer base both domestically and internationally, Bernie is the perfect leader to launch Zila Nutraceuticals into this new phase of growth." Mr. Landes recently served as President of Nutritional Products Group providing services to the dietary supplement, nutraceutical, personal care, environmental, functional and traditional food industries. His other professional accomplishments include serving as Chairman, President and CEO of Paracelsian, Inc., General Manager for Alacer Corp., and Director of Marketing, Strategic Planning, New Product Planning, Regulatory Affairs and Nutrition Science for Health Valley Foods. Mr. Landes has a Bachelor of Science in Business Administration and an MBA in Marketing/Consumer Psychology, both from the University of Delaware. "Ester-C is the industry's most successfully branded vitamin C product. Extending the well-known Ester brand into new delivery forms and categories which are almost limitless, is an exciting opportunity," said Mr. Landes. "When I think of the market potential of combining new product opportunities with entry into some of the world's largest supplement markets, I envision tremendous growth of marketshare for Zila." About Ester-C(R) Ester-C is an advanced form of vitamin C that is pH neutral, providing a form that is easily tolerated by the body. During the patented process of producing Ester-C, the ascorbic acid undergoes changes similar to those that occur in the body, which results in vitamin C metabolites. It is the only vitamin C that contains these metabolites, which help it work differently than regular vitamin C. Ester-C has also been clinically proven to remain active in the immune system for 24 hours. About Ester-E(R) Ester-E is an advanced form of vitamin E containing d-alpha tocopheryl phosphates (or "TP" for short). Until recently, scientists were unaware of this important source of vitamin E in the body. Research suggests that the human body may convert other forms of vitamin E into TP in order to protect the vitamin's antioxidant strength until the body is ready to use it. Scientists are now able to replicate this natural form of vitamin E by joining a phosphate molecule to natural vitamin E in a patented process, preserving vitamin E's natural health benefits until the body is ready to use it. Therefore, Ester-E is protected until it is needed, rather than being used up prematurely. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Visit www.Ester-E.com or www.Ester-C.com for more information about the "Ester" line of premium products. About Zila, Inc. Zila, Inc., headquartered in Phoenix, is an innovator in preventative healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Zila has three business units: -- Zila Pharmaceuticals, marketer of products to promote oral health and prevent oral disease, including ViziLite(R) Plus oral examination kits and Peridex(R) prescription periodontal rinse. -- Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila(R) Tolonium Chloride and OraTest(R) technologies. -- Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and Ester-E(R), branded, highly effective forms of Advanced Protection vitamins C and E. For more information about Zila, visit www.zila.com. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2005.